XBiotech Inc.
XBITXBiotech Inc. in brief
XBiotech Inc. is a listed company in the Biotechnology industry, based in Austin, Texas, USA. Its market value was $61 M on 20 October 2026, which makes it the 20,616th largest listed company in the world and the 3,773rd largest in the USA on this site. It employs about 94 people and Jan-Paul Simard is its chief executive. Its shares trade under the symbol XBIT (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About XBiotech Inc.
Xbiotech is a Clinical Stage Biopharmaceutical company. The company annual revenue is 10.5 million USD. The headquarters is in USA.
XBiotech Inc. timeline
- 2014
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2015
- 🔔Initial public offering on NasdaqFinal prospectus filed with the SEC on 16 April 2015; shares registered for exchange trading on 14 April 2015.
Events of XBiotech Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #2,121 (Jan 2020) · #2,825 (Jan 2021) · #3,314 (Jan 2022) · #4,334 (Dec 2022) · #3,838 (Jul 2023) · #3,531 (Jan 2024) · #2,041 (Mar 2026) · #3,606 (Aug 2026) · #3,717 (Oct 2026) · #3,777 (Oct 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- 0.4×
- Free cash flow yield
- -65.9%
- Net margin
- —
- Operating margin
- —
- Return on equity
- -32.4%
- Liabilities / assets
- 6.5%
- Revenue growth
- -78.2%
- R&D / revenue
- 786.5%
- Profit per employee
- $-484 K
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | — | — | $-56M | $-46M | — |
| Dec 2024 | — | — | $-42M | $-39M | — |
| Dec 2023 | — | — | $-38M | $-25M | — |
| Dec 2022 | $4M | -78.2% | $-34M | $-33M | -820.4% |
| Dec 2021 | $18M | -58.2% | $-25M | $-17M | -94.7% |
| Dec 2020 | $44M | — | $-18M | $-11M | -25.5% |
| Dec 2019 | — | — | $-31M | $669M | — |
| Dec 2018 | — | — | $-21M | $-21M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-40M | $0M | $-40M | $-1.49 | — |
| Dec 2024 | $-31M | $1M | $-32M | $-1.26 | — |
| Dec 2023 | $-19M | $0M | $-19M | $-0.81 | — |
| Dec 2022 | $-15M | $1M | $-15M | $-1.08 | — |
| Dec 2021 | $69M | $4M | $66M | $-0.58 | — |
| Dec 2020 | $-65M | $4M | $-69M | $-0.36 | — |
| Dec 2019 | $-18M | $0M | $-18M | $14.44 | — |
| Dec 2018 | $-17M | $0M | $-17M | $-0.59 | — |
Quarterly results
Latest quarter to Sep 2026: revenue —, net income $-4M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 12, 202610-QQuarterly report · period to Sep 2026
- Oct 26, 20268-KCurrent reportDirectors or officers changed
- Oct 2, 2026DEF 14AProxy statement
- Aug 13, 202610-QQuarterly report · period to Jun 2026
- May 14, 202610-QQuarterly report · period to Mar 2026
- Apr 29, 202610-K/AAnnual report (amended) · period to Dec 2025
- Mar 13, 202610-KAnnual report · period to Dec 2025
- Dec 9, 20258-KCurrent reportDirectors or officers changed
- Nov 12, 202510-QQuarterly report · period to Sep 2025
- Oct 15, 20258-K/ACurrent report (amended)Directors or officers changed
- Oct 3, 20258-KCurrent reportMaterial agreement · Directors or officers changed
- Sep 2, 20258-KCurrent reportShareholder vote
Official filings of XBiotech Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- —
- Operating income
- $-56 M
- Net income
- $-46 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $150 M
- Total liabilities
- $10 M
- Total equity
- $140 M
As of December-2025
Top 34 institutional investors in XBiotech Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 317,527 | -3,619 (-1.13%) | 1.04% | $1 M | Nov 13, 2026 |
| 2 | Geode Capital Management, LLC | 214,116 | 0 (0.00%) | 0.70% | $0 M | Nov 6, 2026 |
| 3 | Vanguard Capital Management LLC | 200,182 | 0 (0.00%) | 0.66% | $0 M | Nov 13, 2026 |
| 4 | RBF Capital, LLC | 198,501 | 0 (0.00%) | 0.65% | $0 M | Nov 13, 2026 |
| 5 | Vanguard Fiduciary Trust Co | 125,691 | +33,326 (+36.08%) | 0.41% | $0 M | Nov 13, 2026 |
| 6 | Morgan Stanley | 123,988 | -23,892 (-16.16%) | 0.41% | $0 M | Nov 13, 2026 |
| 7 | Bridgeway Capital Management, LLC | 98,447 | 0 (0.00%) | 0.32% | $0 M | Nov 16, 2026 |
| 8 | State Street Corp | 73,006 | 0 (0.00%) | 0.24% | $0 M | Nov 12, 2026 |
| 9 | Renaissance Technologies LLC | 67,355 | +25,692 (+61.67%) | 0.22% | $0 M | Nov 12, 2026 |
| 10 | Northern Trust Corp | 60,123 | -6,135 (-9.26%) | 0.20% | $0 M | Nov 16, 2026 |
| 11 | Empowered Funds, LLC | 59,547 | 0 (0.00%) | 0.20% | $0 M | Nov 13, 2026 |
| 12 | Millennium Management LLC | 58,647 | -20,683 (-26.07%) | 0.19% | $0 M | Nov 16, 2026 |
| 13 | Bank of New York Mellon Corp | 39,355 | 0 (0.00%) | 0.13% | $0 M | Nov 5, 2026 |
| 14 | Gsa Capital Partners LLP | 37,995 | +7,341 (+23.95%) | 0.12% | $0 M | Nov 16, 2026 |
| 15 | Dimensional Fund Advisors LP | 35,491 | -562 (-1.56%) | 0.12% | $0 M | Nov 4, 2026 |
| 16 | Allworth Financial LP | 34,725 | New | 0.11% | $0 M | Nov 17, 2026 |
| 17 | Connor, Clark & Lunn Investment Management Ltd. | 27,943 | 0 (0.00%) | 0.09% | $0 M | Nov 10, 2026 |
| 18 | BNP Paribas Financial Markets | 25,400 | -1,064 (-4.02%) | 0.08% | $0 M | Nov 12, 2026 |
| 19 | National Bank Of Canada /fi/ | 25,000 | 0 (0.00%) | 0.08% | $0 M | Nov 16, 2026 |
| 20 | Bank Of America Corp /de/ | 23,789 | 0 (0.00%) | 0.08% | $0 M | Nov 16, 2026 |
| 21 | Squarepoint Ops LLC | 14,941 | -19,816 (-57.01%) | 0.05% | $0 M | Nov 9, 2026 |
| 22 | UBS Group AG | 14,315 | +9,280 (+184.31%) | 0.05% | $0 M | Nov 10, 2026 |
| 23 | American Century Companies Inc | 13,510 | -4,871 (-26.50%) | 0.04% | $0 M | Nov 12, 2026 |
| 24 | Qube Research & Technologies Ltd | 13,485 | -20,085 (-59.83%) | 0.04% | $0 M | Nov 13, 2026 |
| 25 | Pinnacle Financial Partners, Inc. | 11,796 | 0 (0.00%) | 0.04% | $0 M | Nov 13, 2026 |
Show all 34: investors 26 to 34
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Vanguard Global Advisers, LLC | 7,009 | 0 (0.00%) | 0.02% | $0 M | Nov 13, 2026 |
| 27 | Royal Bank Of Canada | 2,908 | +1,702 (+141.13%) | 0.01% | $0 M | Nov 16, 2026 |
| 28 | McIlrath & Eck, LLC | 753 | 0 (0.00%) | 0.00% | $0 M | Nov 17, 2026 |
| 29 | Jones Financial Companies Lllp | 370 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 30 | Jpmorgan Chase & Co | 96 | 0 (0.00%) | 0.00% | $0 M | Nov 12, 2026 |
| 31 | SBI Securities Co., Ltd. | 37 | 0 (0.00%) | 0.00% | $0 M | Oct 22, 2026 |
| 32 | Tower Research Capital LLC (TRC) | 25 | New | 0.00% | $0 M | Nov 16, 2026 |
| 33 | Larson Financial Group LLC | 21 | 0 (0.00%) | 0.00% | $0 M | Nov 5, 2026 |
| 34 | Caitong International Asset Management Co., Ltd | 14 | +3 (+27.27%) | 0.00% | $0 M | Oct 29, 2026 |
Mutual funds holding XBiotech Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 200,182 | $0 M | 0.66% | <0.01% | −0.4% | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 110,502 | $0 M | 0.36% | <0.01% | +8.7% | May 31, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 78,591 | $0 M | 0.26% | 0.01% | +50% | Jun 30, 2026 |
| 🇺🇸 EA Bridgeway Omni Small-Cap Value ETFEmpowered Funds, LLC d/b/a EA Advisers | 59,547 | $0 M | 0.20% | 0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 35,154 | $0 M | 0.12% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 27,507 | $0 M | 0.09% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 16,960 | $0 M | 0.06% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Avantis U.S. Small Cap Equity ETFAmerican Century ETF Trust | 13,228 | $0 M | 0.04% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 JNL/DFA U.S. Small Cap FundJackson National Asset Management, LLC | 6,066 | $0 M | 0.02% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 5,290 | $0 M | 0.02% | <0.01% | +37% | Jun 30, 2026 |
| 🇺🇸 Avantis U.S. Small Cap Value ETFAmerican Century ETF Trust | 4,871 | $0 M | 0.02% | <0.01% | −9.3% | May 31, 2026 |
| 🇺🇸 AST Small-Cap Equity PortfolioAST Investment Services, Inc. | 2,660 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Avantis U.S. Small Cap Value FundAmerican Century ETF Trust | 282 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 13 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at XBiotech Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | John SimardDirector, 10% owner | Buy | +70,000 | $2.049 | $143 K | 4.26 M | Form 4 |
| filed | John SimardDirector, 10% owner | Buy | +368,524 | $1.930 | $711 K | 4.19 M | Form 4 |
| filed | W. Thorpe McKenzieDirector, 10% owner | Option exercise | +250,000 | $10.00 | $2.5 M | 2.81 M | Form 4 |
| filed | W. Thorpe McKenzieDirector, 10% owner | Shares withheld for tax | -213,493 | $11.71 | $2.5 M | 2.60 M | Form 4 |
| filed | John SimardChief Executive Officer, Director, 10% owner | Sell | -33,000 | $13.07 | $431 K | 3.82 M | Form 4 |
| filed | John SimardChief Executive Officer, Director, 10% owner | Sell | -17,000 | $13.32 | $226 K | 3.86 M | Form 4 |
| filed | John SimardChief Executive Officer, Director, 10% owner | Sell | -21,125 | $12.90 | $273 K | 3.87 M | Form 4 |
| filed | John SimardChief Executive Officer, Director, 10% owner | Sell | -10,875 | $12.83 | $140 K | 3.96 M | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: XBiotech Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
| Buybacks, quarter | Fiscal | Spent |
|---|---|---|
| Q4 2024 | Q4 2024 | $0M |
| Q3 2024 | Q3 2024 | $0M |
| Q4 2023 | Q4 2023 | $0M |
| Q3 2023 | Q3 2023 | $0M |
| Q4 2022 | Q4 2023 | $0M |
| Q3 2022 | Q3 2023 | $0M |
Trading halts
- 2024-12-23 14:54 UTC, code LUDP, resumed 15:04 UTC
- 2024-12-23 13:55 UTC, code T3, resumed 14:50 UTC
Fails to deliver
- : 23,318 shares at $2.00
- : 57 shares at $2.18
- : 672 shares at $2.19
- : 11,308 shares at $2.19
- : 617 shares at $2.18
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
XBiotech Inc. scorecard#
Passes 3 of the 12 checks that could be worked out: strongest in valuation (1 of 4), weakest in profitability (0 of 3). Fiscal year 2025; market cap of Oct 20, 2026.
Valuation1 of 4
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✓Price to book below its peers' median0.4×Price to book 0.4× against Biotechnology's median of 2.9×.
- –Price to sales below its peers' medianNo Price to sales on file.
- ✗Free cash flow yield above 5%-65.9%Free cash flow is -65.9% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth0 of 2
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-1.49 vs -1.26Diluted EPS -1.49 in fiscal 2025 against -1.26 the year before (report's currency).
- ✗Net income higher than five years earlier-$46 M-$46 M in fiscal 2025 against -$11 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 3
- ✗Profitable in the newest year-$46 MNet income -$46 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-28.2%-28.2% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 2
- ✓Short-term assets cover short-term liabilities16.0×Current ratio 16.01 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns1 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✓Share count up no more than 2% in a year0.1%Diluted shares up 0.1% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
XBiotech Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | — | — | 0−100%— | 4.0−78.2%100% | 18−58.2%100% | 44—100% | 0—— | 0—— | — | — | |
| Cost of revenue | — | — | 0−100%— | 0.7−88.8%16.2% | 5.8−83.2%31.6% | 35—78.5% | 0—— | 0—— | — | — | |
| Gross profit | — | — | 0−100%— | 3.4−73.3%83.8% | 13+33.1%68.4% | 9.4—21.5% | 0—— | 0—— | — | — | |
| Research and development | 47+25.5%— | 38+14.9%— | 33+4.1%— | 32+11.6%787% | 28+197%154% | 9.5−60.5%21.7% | 24+53.2%— | 16−40.5%— | 26−37.8%— | 42—— | |
| General and administrative | 8.3+76.0%— | 4.7+1.1%— | 4.7−26.1%— | 6.3−32.8%157% | 9.4−48.4%51.0% | 18+155%41.4% | 7.1+35.6%— | 5.3−31.0%— | 7.6−25.7%— | 10—— | |
| Operating expenses | — | 42+13.2%— | 38−0.9%— | 38+0.5%944% | 38+35.8%205% | 28−11.2%63.0% | 31+48.8%— | 21−38.4%— | 34−35.4%— | 53—— | |
| Operating income | −56—— | −42—— | −38—— | −34—−860% | −25—−136% | −18—−41.5% | −31—— | −21—— | −34—— | −53—— | |
| Other non-operating income (expense) | 10+166%— | 3.9−70.4%— | 13+1363%— | 0.9—22.5% | −0.4−107%−2.0% | 5.4−99.3%12.4% | 750—— | −0.1−116%— | 0.9+45350%— | 0.0—— | |
| Income before tax | −45—— | −39—— | −24—— | −34—−838% | −25—−138% | −13−102%−29.2% | 718—— | −21—— | −33—— | −53—— | |
| Income tax | 0.2—— | −0.0−113%— | 0.2—— | −0.7—−17.2% | −8.0—−43.7% | −1.6−103%−3.7% | 50—— | 0—— | 0—— | 0—— | |
| Net income attributable to shareholders | −46—— | −39—— | −25—— | −33—−820% | −17—−94.7% | −11−102%−25.5% | 669—— | −21—— | −33—— | −53r−51—— | |
| Earnings per share, basic | -1.49—— | -1.26—— | -0.81—— | -1.08—— | -0.58—— | -0.36−102%— | 17.17—— | -0.59—— | -0.95—— | -1.63—— | |
| Earnings per share, diluted | -1.49—— | -1.26—— | -0.81—— | -1.08—— | -0.58—— | -0.36−102%— | 14.44—— | -0.59—— | -0.95—— | -1.63—— | |
| Shares, weighted average (basic) | 30+0.1%— | 30+0.1%— | 30−0.0%— | 30+1.3%— | 30−2.5%— | 31−20.9%— | 39+8.8%— | 36+2.7%— | 35—— | — | |
| Shares, weighted average (diluted) | 30+0.1%— | 30+0.1%— | 30−0.0%— | 30+1.3%— | 30−2.5%— | 31−33.5%— | 46+29.4%— | 36+2.7%— | 35+7.6%— | 32—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 126−27.3%83.7% | 173−13.7%86.7% | 200+27.2%88.3% | 157−33.6%63.9% | 237−0.2%86.1% | 237−66.8%67.1% | 715+4416%87.5% | 16−50.2%35.7% | 32−7.4%50.4% | 34—51.2% | |
| Short-term investments | — | — | 0−100%0.0% | 60—24.4% | 0—0.0% | — | — | — | — | — | |
| Receivables | — | 0.7−18.6%0.4% | 0.9−29.3%0.4% | 1.2—0.5% | 0−100%0.0% | 4.1—1.2% | 0—0.0% | — | — | — | |
| Other current assets | 1.0+1.0%0.7% | 1.0+35.8%0.5% | 0.8+26.5%0.3% | 0.6−35.7%0.2% | 0.9+60.5%0.3% | 0.6−65.1%0.2% | 1.7+39.9%0.2% | 1.2−23.7%2.7% | 1.6−40.0%2.5% | 2.6—3.9% | |
| Current assets | 127−27.3%84.6% | 175−13.5%87.7% | 202−8.2%89.0% | 220−10.9%89.3% | 247−24.2%89.7% | 326−54.5%92.1% | 716+4109%87.7% | 17−48.9%38.4% | 33−9.7%52.9% | 37—55.1% | |
| Property, plant and equipment | 23−5.7%15.4% | 25−1.5%12.3% | 25−5.2%11.0% | 26−7.2%10.7% | 28+3.6%10.3% | 27+8.6%7.7% | 25−7.9%3.1% | 27−7.8%61.6% | 30+192%47.1% | 10—15.1% | |
| Total assets | 150−24.6%100% | 199−12.1%100% | 227−7.9%100% | 246−10.6%100% | 275−22.2%100% | 354−56.7%100% | 817+1742%100% | 44r45−29.6%100% | 63−6.1%100% | 67—100% | |
| Accounts payable | 1.5−30.9%1.0% | 2.2−11.6%1.1% | 2.5+4.5%1.1% | 2.4+16.4%1.0% | 2.1−16.9%0.8% | 2.5+15.9%0.7% | 2.1+30.0%0.3% | 1.7−4.5%3.7% | 1.7−61.0%2.7% | 4.4—6.6% | |
| Current liabilities | 7.9−47.5%5.3% | 15+148%7.6% | 6.1+50.0%2.7% | 4.1+17.8%1.7% | 3.5−13.3%1.3% | 4.0−93.4%1.1% | 60+1944%7.4% | 2.9+5.4%6.6% | 2.8−64.9%4.4% | 8.0—11.9% | |
| Total liabilities | 9.7−42.2%6.5% | 17+117%8.5% | 7.8+36.3%3.4% | 5.7−1.6%2.3% | 5.8+13.5%2.1% | 5.1−91.7%1.4% | 61+1978%7.5% | 2.9+4.9%6.6% | 2.8−64.8%4.5% | 8.0—11.9% | |
| Retained earnings | −136—−90.9% | −91—−45.6% | −52—−23.1% | −28−639%−11.3% | 5.2−94.7%1.9% | 98−77.4%27.6% | 431—52.8% | −238—−536% | −217—−344% | −183—−274% | |
| Shareholders' equity | 140−23.0%93.5% | 182−16.7%91.5% | 219−9.0%96.6% | 240−10.8%97.7% | 269−22.7%97.9% | 349−53.9%98.6% | 756+1725%92.5% | 41−31.2%93.4% | 60+1.9%95.5% | 59—88.1% | |
| Total liabilities and equity | 150−24.6%100% | 199−12.1%100% | 227−7.9%100% | 246−10.6%100% | 275−22.2%100% | 354−56.7%100% | 817+1742%100% | 44−29.6%100% | 63−6.1%100% | 67—100% | |
| Shares outstanding | 300.0%— | 30+0.2%— | 30−0.0%— | 300.0%— | 30r30+3.9%— | 29−29.4%— | 42+15.7%— | 36r36+1.3%— | 35+8.6%— | 33—— | |
| Cash-flow statement | |||||||||||
| Share-based compensation | 3.6+107%— | 1.8−46.3%— | 3.3−35.6%— | 5.1+13.4%126% | 4.5−64.5%24.3% | 13+275%28.6% | 3.4+102%— | 1.7−5.1%— | 1.8−68.6%— | 5.6—— | |
| Cash from operating activities | −40—— | −31—— | −19—— | −15−121%−370% | 69—378% | −65—−148% | −18—— | −17—— | −34—— | −46—— | |
| Capital expenditure | −0.3—— | −1.3—— | −0.4—— | −0.6—−14.6% | −3.5—−19.2% | −3.7—−8.5% | −0.2—— | −0.1—— | −1.4—— | −4.7—— | |
| Cash from investing activities | −0.3—— | −1.3−102%— | 61—— | −64—−1593% | −3.5—−19.2% | −3.7−101%−8.5% | 675—— | −0.1—— | −1.4—— | −14—— | |
| Shares issued | — | — | 0.0—— | — | 8.0−22.3%43.5% | 10+171%23.4% | 3.8—— | — | 0.7—— | — | |
| Shares bought back | — | 0—— | −0.0—— | 0—0.0% | — | — | — | — | — | — | |
| Dividends paid | — | — | — | 0—0.0% | −75—−408% | 0—0.0% | 0—— | — | — | — | |
| Cash from financing activities | −10−198%— | 10—— | −0.0—— | 0—0.0% | −67—−364% | −410−1073%−931% | 42+20843%— | 0.2−99.4%— | 33+1032%— | 2.9—— | |
| Exchange-rate effect on cash | 3.3—— | −5.5—— | −0.0—— | −1.0−236%−24.0% | 0.7−48.6%3.8% | 1.4+821%3.1% | 0.1−71.0%— | 0.5—— | −0.8−420%— | 0.3—— | |
| Change in cash | −47—— | −27−164%— | 43—— | −80—−1987% | −0.4—−2.1% | −477−168%−1085% | 699—— | −16—— | −2.6—— | −57—— | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K/A | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | — | — | — | — | — | — | — | — | — | — | — | — | 0*—— | |
| Cost of revenue | — | — | — | — | — | — | — | — | — | — | — | — | 0*—— | |
| Gross profit | — | — | — | — | — | — | — | — | — | — | — | — | 0*—— | |
| Research and development | 41+35.7%— | 4.7−8.3%— | 5.3−0.7%— | 5.2−55.2%— | 25*+224%— | 5.1−28.7%— | 5.3−58.9%— | 12+18.3%— | 7.8*+0.2%— | 7.1—— | 13—— | 9.8—— | 7.8*—— | |
| General and administrative | 7.0+44.6%— | 0.7−31.4%— | 0.9−15.0%— | 1.1−44.7%— | 4.4*+374%— | 1.0+24.5%— | 1.0−49.5%— | 1.9+87.8%— | 0.9*+18.4%— | 0.8—— | 2.0—— | 1.0—— | 0.8*—— | |
| Operating expenses | — | 5.3−12.0%— | 6.1−3.0%— | — | — | 6.0−23.5%— | 6.3−57.7%— | 14+24.9%— | 8.7*+1.9%— | 7.9—— | 15—— | 11—— | 8.6*—— | |
| Operating income | −47—— | −5.3—— | −6.1—— | −6.3—— | −30*—— | −6.0—— | −6.3—— | −14—— | −8.7*—— | −7.9—— | −15—— | −11—— | −8.6—— | |
| Other non-operating income (expense) | 4.1−27.1%— | 0.9+534%— | −0.5−112%— | 0.8−69.6%— | 2.9*—— | 0.1−95.1%— | 4.6+138%— | 2.7+208%— | −1.8*−147%— | 2.9—— | 1.9—— | 0.9—— | 3.9*—— | |
| Income before tax | −43—— | −4.4—— | −6.7—— | −5.5—— | −27*—— | −5.9—— | −1.7—— | −11—— | −11*—— | −5.0—— | −13—— | −10.0—— | −4.7*—— | |
| Income tax | 0.2+74.6%— | 0.0−65.7%— | 0.0+64.3%— | 0.0+69.0%— | 0.1*—— | 0.1+1033%— | 0.0—— | 0.0+16.0%— | −0.0*—— | 0.0—— | −0.0—— | 0.0—— | −0.1*—— | |
| Net income attributable to shareholders | −44—— | −4.5—— | −6.7—— | −5.5—— | −27*—— | −6.0—— | −1.8—— | −11—— | −11*—— | −5.0—— | −13—— | −10—— | −4.6—— | |
| Earnings per share, basic | — | -0.15—— | -0.22—— | -0.18—— | — | -0.20—— | -0.06—— | -0.36—— | — | -0.16—— | -0.43—— | -0.33—— | -0.15—— | |
| Shares, weighted average (basic) | 300.0%— | 300.0%— | 300.0%— | 300.0%— | — | 30+0.0%— | 30+0.1%— | 30+0.1%— | — | 30—— | 30—— | 30—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 105—81.7% | 105−28.7%81.7% | 110−28.4%82.0% | 115−25.9%82.6% | 126−27.3%83.7% | 147−19.5%85.5% | 153−18.9%85.6% | 156−22.5%85.7% | 173−13.7%86.7% | 183—87.3% | 189—87.5% | 201—88.2% | 200—88.3% | |
| Short-term investments | — | — | — | — | — | — | — | — | — | — | — | — | 0—0.0% | |
| Receivables | — | — | — | — | — | 0.5−38.4%0.3% | 0.5−44.8%0.3% | 0.5−44.8%0.3% | 0.7−18.6%0.4% | 0.7—0.3% | 0.9—0.4% | 0.9—0.4% | 0.9—0.4% | |
| Other current assets | 1.1—0.8% | 1.1−0.5%0.8% | 1.3+2.1%1.0% | 1.3+12.0%0.9% | 1.0+1.0%0.7% | 1.1+1.3%0.6% | 1.3+17.7%0.7% | 1.2+7.3%0.6% | 1.0+35.8%0.5% | 1.0—0.5% | 1.1—0.5% | 1.1—0.5% | 0.8—0.3% | |
| Current assets | 106—82.7% | 106−28.6%82.7% | 111−28.2%83.2% | 117−25.8%83.7% | 127−27.3%84.6% | 149−19.5%86.4% | 155−18.8%86.7% | 158−22.3%86.7% | 175−13.5%87.7% | 185—88.2% | 191—88.4% | 203—89.1% | 202—89.0% | |
| Property, plant and equipment | 22—17.3% | 22−5.2%17.3% | 22−5.5%16.8% | 23−5.8%16.3% | 23−5.7%15.4% | 23−5.4%13.6% | 24−4.5%13.3% | 24−2.5%13.3% | 25−1.5%12.3% | 25—11.8% | 25—11.6% | 25—10.9% | 25—11.0% | |
| Total assets | 129—100% | 129−25.4%100% | 134−25.2%100% | 140−23.1%100% | 150−24.6%100% | 172−17.8%100% | 179−17.1%100% | 182−20.2%100% | 199−12.1%100% | 210—100% | 216—100% | 228—100% | 227—100% | |
| Accounts payable | 0.6—0.5% | 0.6−44.3%0.5% | 1.1−22.8%0.8% | 0.9−22.1%0.6% | 1.5−30.9%1.0% | 1.0−30.7%0.6% | 1.4−16.0%0.8% | 1.1−57.8%0.6% | 2.2−11.6%1.1% | 1.5—0.7% | 1.7—0.8% | 2.6—1.1% | 2.5—1.1% | |
| Current liabilities | 2.7—2.1% | 2.7−24.5%2.1% | 3.4−13.1%2.5% | 3.0−44.6%2.1% | 7.9−47.5%5.3% | 3.6−77.7%2.1% | 3.9−77.5%2.2% | 5.4−68.0%3.0% | 15+148%7.6% | 16—7.6% | 17—7.9% | 17—7.4% | 6.1—2.7% | |
| Total liabilities | 4.5—3.5% | 4.5−14.9%3.5% | 5.2−7.6%3.9% | 4.8−32.6%3.4% | 9.7−42.2%6.5% | 5.3−69.9%3.1% | 5.6−70.2%3.1% | 7.2−61.5%3.9% | 17+117%8.5% | 18—8.5% | 19—8.7% | 19—8.2% | 7.8—3.4% | |
| Retained earnings | −153—−119% | −153—−119% | −149—−111% | −142—−101% | −136—−90.9% | −109—−63.5% | −103—−57.9% | −102—−55.9% | −91—−45.6% | −80—−38.3% | −75—−34.9% | −62—−27.3% | −52—−23.1% | |
| Shareholders' equity | 124—96.5% | 124−25.7%96.5% | 128−25.8%96.1% | 135−22.7%96.6% | 140−23.0%93.5% | 167−13.0%96.9% | 173−12.0%96.9% | 175−16.5%96.1% | 182−16.7%91.5% | 192—91.5% | 197—91.3% | 209—91.8% | 219—96.6% | |
| Total liabilities and equity | 129—100% | 129−25.4%100% | 134−25.2%100% | 140−23.1%100% | 150−24.6%100% | 172−17.8%100% | 179−17.1%100% | 182−20.2%100% | 199−12.1%100% | 210—100% | 216—100% | 228—100% | 227—100% | |
| Shares outstanding | 30—— | 300.0%— | 300.0%— | 300.0%— | 300.0%— | 30+0.0%— | 30+0.1%— | 30+0.1%— | 30+0.2%— | 30—— | 30—— | 30—— | 30—— | |
| Cash-flow statement | ||||||||||||||
| Share-based compensation | 0.6−86.1%— | 0.1+167%— | 0.2+60.7%— | 0.2−94.8%— | 0.2*−74.2%— | 0.0−93.4%— | 0.1−71.8%— | 3.3+774%— | 0.6*−8.7%— | 0.4—— | 0.4—— | 0.4—— | 0.7*—— | |
| Cash from operating activities | −41—— | −4.5*—— | −4.5*—— | −9.0—— | −23*—— | −4.3*—— | −6.0*—— | −6.7—— | −6.5*—— | −5.8*—— | −11*—— | −7.2—— | −3.4*—— | |
| Capital expenditure | −0.0—— | −0.0*—— | 0*—— | 0—— | −0.0*—— | −0.1*—— | −0.1*—— | −0.1—— | −0.1*—— | −0.3*—— | −0.6*—— | −0.3—— | −0.1*—— | |
| Cash from investing activities | −0.0—— | −0.0*—— | −0.0*—— | 0.0—— | −0.0*—— | −0.1*—— | −0.1*—— | −0.1—— | −0.1*—— | −0.3*—— | −0.6*—— | −0.3—— | −0.1*—— | |
| Shares issued | — | — | — | — | — | — | — | — | — | 0.1*—— | 0.0*—— | 0.1—— | — | |
| Shares bought back | — | — | — | — | — | — | — | — | 0*—— | 0*—— | — | — | 0*—— | |
| Cash from financing activities | 0—— | 0*—— | 0*—— | 0—— | 0*−100%— | 0*−100%— | 0*−100%— | −10−202%— | 0.3*—— | 0.1*—— | 0.0*—— | 10—— | 0*—— | |
| Exchange-rate effect on cash | −1.3—— | 0.0*—— | −1.4*−146%— | −1.1−499%— | 1.2*—— | −1.2*—— | 3.1*—— | 0.3—— | — | — | — | — | 1.4*—— | |
| Change in cash | −42—— | −4.5*—— | −5.9*—— | −10—— | −22*—— | −5.6*—— | −3.0*—— | −17−1752%— | −10*—— | −5.4*—— | −13*—— | 1.0—— | −2.2*—— | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Executive pay at XBiotech Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Dr. Sushma Shivaswamy | $30.1 M | $27.1 M | $385 K | — |
| 2024Jan-Paul Simard | $6.2 M | $6.2 M | $471 K | $2 |
| 2023Jan-Paul Simard | $5.6 M | $5.6 M | $500 K | $14 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at XBiotech Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
- Delisting noticeFiling
Delisting notice 1 · Directors and officers 8 · Material agreement 2 · New debt 1 · Unregistered share sale 1 · Shareholder vote 4
| Filed | What happened | Filing |
|---|---|---|
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K/A | |
| Directors and officersMaterial agreement | 8-K | |
| Shareholder vote | 8-K | |
| Directors and officers | 8-K | |
| Delisting notice | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Shareholder vote | 8-K | |
| Material agreementNew debtUnregistered share sale | 8-K | |
| Shareholder vote | 8-K | |
| Directors and officers | 8-K | |
| Shareholder vote | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Oct 26, 2026
How XBiotech Inc. compares in Biotechnology
- Market cap$61 M · higher than 29% of 726
- Revenue growth-78.2% · higher than 7% of 438
- Price / book0.4× · lower than 94% of 534
- FCF yield-65.9% · higher than 19% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| XBiotech Inc.🇺🇸 | $61 M | — | — | -78.2% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 20, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As on June 2021
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at XBiotech Inc.? Verify and update this profile — free
Show XBiotech Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.